CemiplimAb-rwlc Survivorship and Epidemiology (CASE): A prospective study of the safety and efficacy of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC) in a real-world setting. (2023). SKIN The Journal of Cutaneous Medicine, 7(2), s174. https://doi.org/10.25251/skin.7.supp.174